Both nusinersen and tofersen, approved ASO drugs for the treatment of spinal muscular atrophy and SOD1-driven ALS, respectively, are administered directly to the CNS through intrathecal infusions. This evidence concerns the gene SOD1 and proximal spinal muscular atrophy.